Advertisement
UK markets closed
  • FTSE 100

    7,959.93
    +27.95 (+0.35%)
     
  • FTSE 250

    19,911.36
    +100.70 (+0.51%)
     
  • AIM

    744.47
    +2.36 (+0.32%)
     
  • GBP/EUR

    1.1701
    +0.0032 (+0.28%)
     
  • GBP/USD

    1.2643
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    56,039.02
    +1,345.66 (+2.46%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,251.07
    +2.58 (+0.05%)
     
  • DOW

    39,765.05
    +4.97 (+0.01%)
     
  • CRUDE OIL

    82.76
    +1.41 (+1.73%)
     
  • GOLD FUTURES

    2,241.50
    +28.80 (+1.30%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,504.51
    +27.42 (+0.15%)
     
  • CAC 40

    8,212.41
    +7.60 (+0.09%)
     

What Analysts Recommend for CymaBay Therapeutics

What Analysts Recommend for CymaBay Therapeutics

CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.